Maoye International (00848) announced its annual performance, with a net loss attributable to shareholders of 507 million yuan, a year-on-year increase of 421.87%.
Mega International (00848) released its annual results for the year ending December 31, 2025. The group achieved a revenue of 3.035 billion yuan, a decrease of 24.48% year-on-year. The company's ordinary shareholders' loss was 507 million yuan, an increase of 421.87% year-on-year, with a loss per share of 9.87 cents.
MAOYE INT'L (00848) released its annual performance for the year ending December 31, 2025. The group achieved a revenue of 3.035 billion yuan, a year-on-year decrease of 24.48%; the net loss attributable to ordinary shareholders of the company was 507 million yuan, a year-on-year increase of 421.87%; with a loss per share of 9.87 cents.
As one of the leading middle to high-end physical retailers in China, the group has been committed to creating a good reputation and continuously attracting new and old customers through a diverse range of products and improved consumer experience. During the reporting period, the group focused on its core business, consolidated its resilience and strength in the complex and ever-changing market environment, continuously improved the quality of operations management, fully tapped into the performance growth potential of high-quality product resources, continued to strengthen its brand adjustment and creative marketing efforts, gradually restored its operating situation, and achieved sustained healthy development.
Related Articles

GLOBAL BIO-CHEM (00809) has released its annual performance, with an annual profit of HK$156 million, a decrease of 79.69% year-on-year.

RAILY AESMED (02135): Lin Hai appointed as an independent non-executive director of the company.

RAILY AESMED (02135) announces annual performance, with net profit attributable to shareholders of 1.873 million yuan, turning loss into profit year-on-year.
GLOBAL BIO-CHEM (00809) has released its annual performance, with an annual profit of HK$156 million, a decrease of 79.69% year-on-year.

RAILY AESMED (02135): Lin Hai appointed as an independent non-executive director of the company.

RAILY AESMED (02135) announces annual performance, with net profit attributable to shareholders of 1.873 million yuan, turning loss into profit year-on-year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


